8-K: Inhibrx Biosciences Reports Positive Phase 2 Data for INBRX-106

Inhibrx Biosciences announced positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer, showing a significant increase in objective response rates when combined with pembrolizumab.

Summary

• Inhibrx Biosciences presented positive interim Phase 2 data from the HexAgon study for INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab for first-line Head and Neck Squamous Cell Carcinoma (HNSCC) patients with high PD-L1 expression (CPS ≥ 20).
• In the evaluable population of 53 patients (25 in the combination arm, 28 in the control arm), the INBRX-106 combination achieved a confirmed objective response rate (cORR) of 44.0%, compared to 21.4% for pembrolizumab monotherapy, an absolute increase of 22.6%.
• Three complete responses were observed in the combination arm, versus none in the control arm.
• Pharmacodynamic data showed up to a 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and up to a four-fold increase in activation in combination-treated patients.
• The combination demonstrated a manageable safety profile, consistent with immunotherapy combinations, with no treatment-related deaths reported.
• Progression-free survival data is expected in Q4 2026, and the Phase 3 portion of the HexAgon study is planned to begin in Q3 2026.
• Inhibrx plans to evaluate INBRX-106 in broader indications, including perioperative non-small cell lung cancer (NSCLC) starting this quarter, and front-line metastatic NSCLC in 2027.
• The estimated total market size for HNSCC with high PD-L1 expression is $1 billion, with potential expansion into NSCLC and other checkpoint inhibitor indications representing a total market opportunity of approximately $50 billion.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development due to the significant improvement in response rates and the promising mechanistic data, supporting future clinical development and market potential.

Positives

• Demonstrated a 22.6% absolute increase in confirmed objective response rate (44.0% vs. 21.4%) in first-line HNSCC patients.
• Achieved three complete responses in the combination arm, where none were seen with pembrolizumab alone.
• Showed robust pharmacodynamic effects with up to a 15-fold increase in T-cell proliferation and up to a four-fold increase in T-cell activation.
• The combination therapy exhibited a manageable safety profile with no treatment-related deaths.
• Positive interim results support the initiation of the Phase 3 HexAgon study in Q3 2026.
• Plans to expand INBRX-106 evaluation into significant markets like NSCLC, with studies planned for this quarter and 2027.
• The potential total addressable market, including NSCLC and other indications, is estimated at $50 billion.

Negatives

• 15 patients in the overall population were not included in this analysis as they had not yet reached the maturity threshold for response confirmation or were not evaluable.
• The study focused on patients with high PD-L1 expression (CPS ≥ 20), which may limit generalizability to broader patient populations.
• While manageable, adverse events such as rash, diarrhea, and fatigue were reported.

Risks

• Topline data may not accurately reflect complete results and remain subject to audit; final data may differ materially.
• Initiation, timing, progress, and results of clinical trials are subject to inherent uncertainties.
• Unexpected adverse side effects or inadequate efficacy could limit development, approval, or commercialization.
• Competitor developments, including study results or regulatory determinations, could negatively impact programs.
• Regulatory filings and approvals, as well as regulatory developments in the U.S. and foreign countries, carry inherent risks.
• Successful commercialization, pricing, coverage, and reimbursement are not guaranteed.
• The interpretation of interim or preliminary data may not be predictive of future results.

Future Outlook

The company plans to initiate the Phase 3 portion of the HexAgon study in Q3 2026 and expects progression-free survival data in Q4 2026. Inhibrx also intends to evaluate INBRX-106 in broader indications, including perioperative NSCLC starting this quarter and front-line metastatic NSCLC in 2027, and explore combinations with other therapeutic modalities.

Management Comments

• "We are greatly encouraged by these early clinical results," said Mark Lappe, Chief Executive Officer of Inhibrx. "These data, coupled with the clear evidence of T-cell expansion and superior depth of response, give us confidence that INBRX-106 could be the first costimulatory agent to fundamentally shift the efficacy ceiling of immunotherapy, and open the door to combinations with new modalities that could be enhanced by OX40 agonism."

Industry Context

StockSavvy.ai notes that the positive interim results for INBRX-106 in HNSCC align with the industry trend of developing combination immunotherapies to enhance the efficacy of existing checkpoint inhibitors. The focus on OX40 agonism as a next-generation costimulatory approach addresses the need for improved treatment outcomes in difficult-to-treat cancers.

Comparison to Industry Standards

• The confirmed objective response rate (cORR) of 44.0% for INBRX-106 plus pembrolizumab in first-line HNSCC (CPS ≥ 20) significantly surpasses the cORR of 21.4% observed with pembrolizumab monotherapy in the control arm, which is benchmarked against the KEYNOTE-048 study's findings for pembrolizumab in similar patient populations.
• The achievement of three complete responses in the combination arm is notable, as complete responses are generally associated with more durable outcomes and remain uncommon in first-line HNSCC treatment.
• The pharmacodynamic data showing enhanced T-cell proliferation and activation supports the mechanistic hypothesis for INBRX-106's benefit, a critical factor in evaluating novel immuno-oncology agents against established standards of care.

Stakeholder Impact

• Shareholders: Positive clinical data may lead to increased investor confidence and potential stock price appreciation.
• Patients: Potential for improved treatment outcomes and more durable responses in HNSCC and future indications.
• Healthcare Providers: New therapeutic option with demonstrated benefit over current standard of care in a specific patient population.
• Competitors: Increased competitive pressure in the immuno-oncology space, particularly for OX40 agonists and combination therapies.

Next Steps

• Initiate Phase 3 portion of the HexAgon study in Q3 2026.
• Evaluate INBRX-106 in perioperative NSCLC starting this quarter.
• Begin planning for expansion into front-line metastatic NSCLC setting with studies expected in 2027.
• Explore combinations of INBRX-106 with other agents like vaccines, T-cell engagers, and CAR-Ts.
• Present progression-free survival data from the Phase 2 HexAgon study in Q4 2026.

Key Dates

Recommendation

The strong positive interim Phase 2 data for INBRX-106, demonstrating a significant improvement in objective response rates and complete responses compared to the current standard of care (pembrolizumab monotherapy) in a well-defined patient population, coupled with robust pharmacodynamic support and a clear path for Phase 3 development and expansion into other major indications like NSCLC, warrants a strong buy recommendation.

Keywords

INBRX-106, HNSCC, Head and Neck Cancer, OX40 agonist, Pembrolizumab, Immunotherapy, Clinical Trial, Phase 2